arginyl-glycyl-aspartic acid and Central Nervous System Neoplasms

arginyl-glycyl-aspartic acid has been researched along with Central Nervous System Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, T; Fu, Y; Gong, T; Song, X; Yang, L; Zhang, Z	1
Chen, Z; Diao, Y; Hou, J; Li, W; Wu, Y; Yang, Z; Zhang, L	1
Mikkelsen, T; Nabors, LB; Reardon, DA; Stupp, R	1

Reviews

1 review(s) available for arginyl-glycyl-aspartic acid and Central Nervous System Neoplasms

Article	Year
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:8 Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Integrins; Models, Molecular; Oligopeptides; Protein Binding; Snake Venoms; Treatment Outcome	2008

Article

Year

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.

Expert opinion on investigational drugs, 2008, Volume: 17, Issue:8

Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Glioblastoma; Humans; Integrins; Models, Molecular; Oligopeptides; Protein Binding; Snake Venoms; Treatment Outcome

2008

Other Studies

2 other study(ies) available for arginyl-glycyl-aspartic acid and Central Nervous System Neoplasms

Article	Year
nRGD modified lycobetaine and octreotide combination delivery system to overcome multiple barriers and enhance anti-glioma efficacy. Colloids and surfaces. B, Biointerfaces, 2017, Aug-01, Volume: 156 Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents, Hormonal; Cell Proliferation; Central Nervous System Neoplasms; Drug Delivery Systems; Glioma; Indolizines; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Octreotide; Oligopeptides; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured	2017
RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy. International journal of pharmaceutics, 2016, May-30, Volume: 505, Issue:1-2 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Central Nervous System Neoplasms; Diphenylamine; Drug Delivery Systems; Drug Liberation; Drug Synergism; Female; Glioblastoma; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Oligopeptides; Xenograft Model Antitumor Assays	2016

Article

Year

nRGD modified lycobetaine and octreotide combination delivery system to overcome multiple barriers and enhance anti-glioma efficacy.

Colloids and surfaces. B, Biointerfaces, 2017, Aug-01, Volume: 156

Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents, Hormonal; Cell Proliferation; Central Nervous System Neoplasms; Drug Delivery Systems; Glioma; Indolizines; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Octreotide; Oligopeptides; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured

2017

RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy.

International journal of pharmaceutics, 2016, May-30, Volume: 505, Issue:1-2

Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Central Nervous System Neoplasms; Diphenylamine; Drug Delivery Systems; Drug Liberation; Drug Synergism; Female; Glioblastoma; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Oligopeptides; Xenograft Model Antitumor Assays

2016